This month’s people on the move includes a new therapeutic lead at Advanced Clinical, with plans to create a network of investigation sites, as well as CEOs at AIT Bioscience and Pharm-Olam, who discuss plans for moving forward.
This month’s people on the move includes a new therapeutic lead at Advanced Clinical, with plans to create a network of investigation sites, as well as CEOs at AIT Bioscience and Pharm-Olam, who discuss plans for moving forward.
Dr. Pavel Tyan is a surgeon, oncologist, and researcher, and now, has been appointed at the therapeutic lead for oncology at Advanced Clinical. Tyan has worked across both the pharmaceutical and CRO industries, with a focus on immuno-oncology programs.
“My ultimate goal is to make Advanced Clinical visible for oncology-focused pharma and biotech in Europe and worldwide, to demonstrate that Advanced Clinical could be the right and attractive partner for clinical trials execution in oncology,” he told us.
To meet this goal, Tyan said supporting activities will include developing a ‘foundation’ of high performing investigational sites, which will enable the company’s clients “to get the quick access to scientific expert’s advices, desired patient’s population as well as the good quality clinical trial data.”
Initial discussions with European research centers are underway, Tyan said, adding that he has received positive feedback from the sites expressing a ‘high interest’ to collaborate.
“The plan is to embrace not only such traditional for oncology clinical research in Europe countries like Central and Western European countries but to extend the Advanced Clinical outreach farther east to Russia and its neighboring countries which possess tremendous potential for oncology clinical trials,” he explained.
“In addition, I believe that my vision on how to ensure the medical monitoring excellence specifically in oncology clinical trials, developed through the years of experience of working for numerous pharmaceutical companies, biotech and CROs will find the fertile ground in this very dynamic, collaborative and open-minded atmosphere at Advanced Clinical.”
BioIVT in October named Lori Ball as its chief operating officer (COO), a role in which she will help lead the company’s operational and business decisions.
“I have a deep passion for life science and research because I have personally witnessed the impact of such developments on my friends and family,” Ball told us.
“BioIVT has been instrumental to many scientific breakthroughs and I am humbled to become a part of such a well-established industry leader. I am looking forward to building upon BioIVT’s strategic vision to positively impact treatment outcomes and improve human health.”
Ball was previously the president and CEO of the business strategy consultancy in the life sciences industry, LAB Strategies. Prior to that, she was president and COO of BioStorage Technologies and worked at Covance for seven years. She also co-founded of The Global Initiative for the Ethical use of Human Specimens (the GIFT Initiative).
Richard Clarke has been named the commercial and patient solutions business development director at Ashfield. This department designs and delivers nurse-led patient support services.
Clarke has more than 30 years of experience in the pharmaceutical industry and held roles at a national and global level within GSK and AstraZeneca.
Said Clarke: “I am delighted to be joining at this exciting time for the UK business, and to be part of the Ashfield team."
Pharm-Olam’s board of directors has elected Robert Davie, PhD, as the company’s new chief executive officer.
Davie succeeds David Grange, who will remain a director and vice chairman of the company’s board, supporting its work in US government-funded research.
“This is a very exciting time as I join and take the helm of my new company, Pharm-Olam,” Davie said. “I am focused on continuing to develop the strengths Pharm-Olam is known for – particularly our ability as a midsized CRO to be more nimble and responsive to our clients’ needs.”
In his first 90 days, Davie said he will be assessing where the company plans to further invest resources to enhance its therapeutic areas, including infectious disease, oncology-hematology and allergy, “with our significant strengths in rare disease and orphan drugs running across all.”
Previously Davie worked at Covance and was most recently the vice president and general manager of the global clinical development.
The contract manufacturing organization (CMO) and pharmaceutical supply service company has hired Sherry Ann D’Iorio to the role of executive director of business development.
“I’m excited to join Experic to lead the Business Development initiatives on the West Coast. I look forward to working with our internal team of industry experts to develop customized solutions and flexible strategies to support our client’s manufacturing and packaging needs,” D’Iorio told us.
“My initial efforts will be focused on increasing awareness of Experic services, its state-of-the-art cGMP facility, and its partnership with Harro Höfliger,” added D’Iorio, who has more than 20 years of experience in the CRO and life science industry.
The bioanalytical contract research organization (CRO) has named a new CEO, Jeff Goddard, who also will join the company’s board of directors.
“I’d like to continue building on the forward thinking vision of AIT Bioscience’s founders to become the bioanalytical partner of choice for biopharmaceutical and animal health companies as they discover and develop new therapies,” Goddard told us.
Goddard has worked for both start-ups to Fortune 500 firms, holding various positions at EPL Archives (acquired by VWR International in 2017), Biostorage Technologies (now Brooks Life Science), Gene Logic, and Nalco Chemical Company.
The life science regulatory, quality and clinical consulting firm has promoted Greg Dombal to president, Tania Zieja to chief financial officer and Katie McCarthy to chief development officer.
The company also has expanded its operation in San Diego, increasing increased its headcount to more than 90 full-time employees with roles across its regulatory, clinical, and quality practices.
Dombal told us the company brings real world experience to its clients. This includes strategic planning among other areas that he said have fueled Halloran’s growth over the past decade.
“I’ve had the pleasure of working with some savvy, creative and thoughtful human beings at Halloran and I look forward to continuing to lead and support the team to provide remarkable clinical, quality, regulatory and talent solutions to enable our clients to positively impact human health,” Dombal said.
Zieja has her eyes set on streamlining internal workflows to effectively broaden the company’s focus from how it gets data, to having a conversation about the data, she said.
“The financial workstreams that run parallel to the support that we are providing to clients tells a lot about health and financial trends that could be informative in how we pivot to meet demand,” she told us. She also said she plans to “further empower managers to effectively hire, manage, develop and collaborate with their team members.”
Looking forward to continuing to grow the Halloran’s team and capabilities, McCarthy said demand for its regulatory, clinical, quality, program leadership, and organizational consulting continues to rise.
“We play a key role in advising clients on optimal development and organizational strategies and delivering the regulatory, clinical, and quality work that’s required to advance products into and through development and ideally, into the hands of patients and physicians,” she told us.
“The life science industry is doing some incredible things – and we’re excited to be a part of it.”
